Second primaries for over 25 percent with metastatic prostate cancer

Second primaries for over 25% with metastatic prostate cancer

(HealthDay)—More than one-quarter of patients with metastatic prostate cancer present with a synchronous second primary malignancy, according to a review published in the April issue of The Journal of Urology.

Kyo Chul Koo, M.D., Ph.D., from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues conducted a retrospective record review of 582 consecutive patents with diagnosed with metastasis. The authors examined the prognostic impact of a synchronous second primary malignancy, defined as a cytologically or histologically proven solid malignancy, on overall survival.

The researchers found that 28.1 percent of patients had a synchronous second primary malignancy, of which the most prevalent types were colorectal (9.1 percent), stomach (7.3 percent), and lung (7.1 percent) cancers. During a median follow-up of 34.1 months, the rate of overall survival was significantly higher for patients without a synchronous secondary primary malignancy versus those with lung or . Outcomes were comparable for men without a second malignancy and for those with . Independent predictors of overall mortality included clinical stage T4 or greater, American Society of Anesthesiologists score 1 or greater, and lung or stomach cancer.

"A substantial proportion of patients with present with a synchronous second primary malignancy," the authors write. "Definitive therapy targeting prostate cancer may confer a limited survival benefit in patients with synchronous lung or stomach cancer."

Explore further

Fitness level associated with lower risk of some cancers, death in men

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Journal of Urology

Copyright © 2015 HealthDay. All rights reserved.

Citation: Second primaries for over 25 percent with metastatic prostate cancer (2015, April 23) retrieved 7 April 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments